Read More Pharma Industry News AstraZeneca’s Tagrisso redefines survival bar in advanced EGFR-mutant NSCLC AstraZeneca’s Tagrisso combo extends survival to nearly 4 years in advanced EGFR-mutated lung cancer. Find out what this means for treatment norms. byPallavi MadhirajuSeptember 7, 2025